JCO at ASCO 2026: Individualized Neoantigen Therapy Plus Pembrolizumab in Melanoma
JCO Editorial Fellow Dr. Ash Gurumurthi and JCO Associate Editor Dr. Grant McArthur discuss the ASCO 2026 Simultaneous Publication paper "Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase 2b KEYNOTE-942 Study." LINK TO FULL TRANSCRIPT
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from Journal of Clinical Oncology (JCO) Podcast
JCO Article Insights: Duvelisib in Patients with Relapsed or Refractory PTCL
Effectiveness of a Virtual Tobacco Treatment for Cancer Patients
Phase 2 Study of Multi-Cancer Detection from Breath Samples
JCO at ASCO 2026: Pemigatinib Phase 3 FIGHT-302 Trial in Cholangiocarcinoma
Get summaries like this every morning.
Free AI-powered recaps of Journal of Clinical Oncology (JCO) Podcast and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.